Journal of Drugs in Dermatology - The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris
January 1, 2005 -- Abstract Clindamycin phosphate is the most widely used topical antibacterial agent for acne treatment. Treatment of patients with mild to moderate...
Business Wire - Abraxis BioScience Receives FDA Approvals for Clindamycin Injection, USP
May 10, 2007 -- LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced that it has received two...
OB/GYN News - Once-daily clindamycin foam easier for patients
April 15, 2005 -- Compliance among adults and adolescents with acne vulgaris may improve with once-a-day clindamycin foam, which has been approved by the Food and Drug...
Internal Medicine News - Clindamycin foam may boost acne compliance
February 1, 2005 -- Compliance with acne treatment may improve with once-a-day clindamycin foam, which has been approved by the Food and Drug Administration. The new...
Pediatric News - Combination gel Ziana improves acne lesions
October 1, 2007 -- CHICAGO -- An aqueous gel formula that combines 0.025% tretinoin and 1.2% clindamycin phosphate significantly reduces both inflammatory and...
Internal Medicine News - Combination gel improves acne in phase III study
September 15, 2007 -- CHICAGO -- An aqueous gel formula that combines 0.025% tretinoin and 1.2% clindamycin phosphate significantly reduces inflammatory and...
Business Wire - Ipsen and Medicis Announce Submission of Reloxin® in Aesthetics to the FDA
December 6, 2007 -- PARIS & SCOTTSDALE, Ariz. -- Regulatory News: Ipsen (Paris:IPN) and Medicis (NYSE:MRX) today announced the submission of the Biologics License...
Skin & Allergy News - Combination gel improves acne in phase III study
September 1, 2007 -- CHICAGO -- An aqueous gel formula that combines 0.025% tretinoin and 1.2% clindamycin phosphate significantly reduces inflammatory and...
Pediatric News - Acne treatment for the back
July 1, 2007 -- ClindaReach is indicated for the treatment of acne vulgaris in hard-to-reach places, such as the patient's back. Each package of this dermatological...
Journal of Drugs in Dermatology - The clinical impact of vehicle technology using a patented formulation of benzoyl peroxide 5%/clindamycin 1% gel: comparative assessments of skin tolerability...
February 1, 2006 -- Abstract A major challenge encountered in clinical practice in patients with acne vulgaris is irritation related to topical medications used for...
